Eli Lilly's Adjusted Dosing of Kisunla Shows Significant Reduction in Brain Swelling for Alzheimer's Patients

Kisunla, Eli Lilly's Alzheimer's disease therapy, gained FDA approval in July for treating adults with early symptomatic Alzheimer's disease. Initially, the dosing regimen involved a 700 mg infusion followed by 1,400 mg every four weeks, but this approach had raised safety concerns due to an imbalance of deaths among patients[1]. In response, the company conducted the Phase IIIb TRAILBLAZER-ALZ 6 study, which introduced a modified dosing schedule. This adjusted regimen starts at 350 mg and gradually increases the dosage, demonstrating a significant reduction in the risk of brain swelling incidents, particularly for those with a genetic predisposition to Alzheimer's[2].